ANDEMBRY

CSL Behring GmbH

Application Filed: 2020-12-21

Trademark Application Details

Mark For: ANDEMBRY® trademark registration is intended to cover the categories of pharmaceutical preparations; antibodies; blood products; blood plasma; blood plasma fractions; blood plasma products for medical purposes; recombinant proteins for medical purposes; cell cultures for medical purposes.

Status

2020-12-24 UTC

LIVE APPLICATION Awaiting Examination

The trademark application has been accepted by the Office (has met the minimum filing requirements) and has not yet been assigned to an examiner.

Research	OneLook Acronym Finder
Serial Number	90398123
Registration Number	6626006
Mark Literal Elements	ANDEMBRY
Mark Drawing Type	4 - STANDARD CHARACTER MARK
Mark Type	Trademark
Current Location	NEW APPLICATION PROCESSING 2020-12-24
Basis	44(d)
Class Status	ACTIVE
Primary US Classes	005: Adhesives 006: Chemicals and Chemical Compositions 018: Medicines and Pharmaceutical Preparations 044: Dental, Medical and Surgical Appliances 046: Foods and Ingredients of Foods 051: Cosmetics and Toilet Preparations 052: Detergents and Soaps
Primary International Class	005 - Primary Class (Pharmaceuticals) Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
Filed Use	No
Current Use	No
Intent To Use	No
Filed ITU	No
44D Filed	Yes
44E Current	No
66A Current	No
Current Basis	No
No Basis	No
Domestic Representative	Scott D. Woldow
Attorney Name	Scott D. Woldow
Attorney Docket Number	034845.254

Timeline

2020-12-21	Application Filed
2020-12-24	Location: NEW APPLICATION PROCESSING
2020-12-24	Status: Live/Pending
2020-12-24	Status: New application will be assigned to an examining attorney approximately 3 months after filing date.
2020-12-24	Transaction Date
2022-01-25	Trademark Registered

Trademark Parties (Applicants & Owners)

Party:	CSL Behring GmbH
Address	Emil-von-Behring Str. 76 Marburg GERMANY D-35041
Legal Entity Type	Limited Liability Company
Legal Entity State	GERMANY

Documents

Application	MULTI	2020-12-21
Drawing	JPEG	2020-12-21

Attorney of Record

SCOTT D. WOLDOW
SMITH, GAMBRELL & RUSSELL, LLP
1055 THOMAS JEFFERSON STREET, NW
SUITE 400
WASHINGTON, DC 20007

Good, Services, and Codes

International Codes:	5
U.S. Codes:	005,006,018,044,046,051,052

Type Code	Type
GS0051	Pharmaceutical preparations; antibodies; blood products; blood plasma; blood plasma fractions; blood plasma products for medical purposes; recombinant proteins for medical purposes; cell cultures for medical purposes
GS0051	Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE

Type Code

Type

GS0051

Pharmaceutical preparations; antibodies; blood products; blood plasma; blood plasma fractions; blood plasma products for medical purposes; recombinant proteins for medical purposes; cell cultures for medical purposes

GS0051

Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE

Trademark Filing History

Description	Date	Proceeding Number
NEW APPLICATION ENTERED IN TRAM	2020-12-24

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.